Merck’s COVID tablet shows a decrease in modified research | Coronavirus Plague News

Drugs claim that the final analysis of experimental results showed that molnupiravir reduced 30 percent of hospital mortality and mortality, compared with approximately 50 percent in the interim study.

Merck’s product COVID-19 test tablet is less effective in reducing hospital mortality and mortality than previously reported, the company said, following a comprehensive analysis of test results.

The U.S.-based company said Friday oral medication, molnupiravir, showed a 30 percent reduction in hospital mortality compared to placebo, according to more than 1,400 patients.

Last month, the company said what 775 patients showed showed the reduction was “about” 50 percent.

In the modified version, one death was reported in the molnupiravir arm of the study, as opposed to nine in the placebo group.

Merck filed a US patent for molnupiravir on October 11, following the incident.

The release of the full analysis came before the U.S. Food and Drug Administration (FDA) released a statement Friday seeking to inform a panel of foreign experts meeting Tuesday to discuss whether to approve the approval of the pills.

Staff at the agency did not comment on whether the pills would be approved.

Officials at the FDA asked the team to discuss whether the benefits of the drug outweigh its risks and whether the number of people to whom the drug should be approved should be kept.

He also asked the committee to reconsider whether the drug could stimulate the virus to change, and how the anxiety could be reduced.

Merck shares fell nearly 3 percent to $ 80 in the first sell-off when the market crashed due to news reports. a new type of coronavirus.

Pills such as molnupiravir and paxlovid, a competing drug manufactured by Pfizer, have been cited as a game changer because they can be taken as home remedies to prevent hospitalization and death.

Data from Pfizer tablet, following a study of 1,200 people, showed a 89 percent reduction in the risk of hospitalization or death due to coronavirus compared with placebo.

The two experimental drugs have different mechanisms of action. Merck’s was designed to point out flaws in the virus’ genes. Pfizer, a component of a group called protease inhibitors, was developed to inhibit the enzyme that coronavirus must secrete.

Last week, the European Union’s health watchdog advised the member states may use Merck’s COVID-19 antivirus tablets in the event of an emergency due to the increased risk of infection, before treatment is approved in all areas.

The United Kingdom approved molnupiravir, called Lagevrio, earlier this month.